Skip to main content

Advertisement

SpringerLink
Log in

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale

  • Take a Closer Look at Trials
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

The December 2003 report from the National Institute of Neurological Disorders and Stroke (NINDS) Workshop on priorities for clinical research in intracerebral hemorrhage (ICH) recommended clinical trials for evaluation of blood pressure management in acute ICH as a leading priority. The Special Writing Group of the Stroke Council of the American Heart Association in 1999 and 2007 emphasized the need for clinical trials to ensure evidence-based treatment of acute hypertensive response in ICH. To address important gaps in knowledge, we conducted a pilot study funded by the NINDS, Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) I Trial, during 2004–2008 to determine the appropriate level of systolic blood pressure (SBP) reduction. We now have initiated a multi-center, randomized Phase III trial, the ATACH II Trial, to definitively determine the efficacy of early, intensive, antihypertensive treatment using intravenous (IV) nicardipine initiated within 3 h of onset of ICH and continued for the next 24 h in subjects with spontaneous supratentorial ICH. The primary hypothesis of this large (N = 1,280), streamlined, and focused trial is that SBP reduction to ≤140 mm Hg reduces the likelihood of death or disability at 3 months after ICH, defined by modified Rankin scale score of 4–6, by at least 10% absolute compared to standard SBP reduction to ≤180 mm Hg. The ATACH II trial is a natural extension of numerous case series, the subsequent ATACH I pilot trial, and a preliminary, randomized, and controlled trial in this patient population funded by the Australian National Health and Medical Research Council. Both trials recently confirmed the safety and tolerability of both the regimen and goals of antihypertensive treatment in acutely hypertensive patients with ICH, as proposed in the present trial. The underlying mechanism for this expected beneficial effect of intensive treatment is presumably mediated through reduction of the rate and magnitude of hematoma expansion observed in approximately 73% of the patients with acute ICH. The Australian trial provided preliminary evidence of attenuation of hematoma expansion with intensive SBP reduction. The ATACH II trial will have important public health implications by providing evidence of, or lack thereof, regarding the efficacy and safety of acute antihypertensive treatment in subjects with ICH. This treatment represents a strategy that can be made widely available without the need for specialized equipment and personnel, and therefore, can make a major impact upon clinical practice for treating patients with ICH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450–60.

    Article  PubMed  CAS  Google Scholar 

  2. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007;25:32–8.

    Article  PubMed  Google Scholar 

  3. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905–15.

    Article  PubMed  CAS  Google Scholar 

  4. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:2001–23.

    Google Scholar 

  5. Flaherty ML, Woo D, Haverbusch M, et al. Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. Stroke. 2005;36:2660–4.

    Article  PubMed  Google Scholar 

  6. Steiner T, Kaste M, Forsting M, et al. Recommendations for the management of intracranial haemorrhage—part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294–316.

    Article  PubMed  Google Scholar 

  7. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery. 2005;57:837–44.

    Article  PubMed  Google Scholar 

  8. Nishiyama T, Yokoyama T, Matsukawa T, Hanaoka K. Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage. Can J Anaesth. 2000;47:1196–201.

    Article  PubMed  CAS  Google Scholar 

  9. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364–7.

    Article  PubMed  Google Scholar 

  10. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.

    Article  PubMed  CAS  Google Scholar 

  11. Mayer SA. Factor seven for acute hemorrhagic stroke (FAST) study. In: 16th European Stroke Conference: Large Clinical Trials 1. Abstract 1 29 May–1 June 2007.

  12. Mayer SA, Davis SM, Begtrup K, et al. Subgroup analysis in the Fast trial: A subset of intracerebral hemorrhage patients that benefit from recombinant activated factor VII. Stroke. 2008;39:528.

    Article  Google Scholar 

  13. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27:1783–7.

    Article  PubMed  CAS  Google Scholar 

  14. Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology. 1994;44:1379–84.

    PubMed  CAS  Google Scholar 

  15. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality [see comment]. Stroke. 1993;24:987–93.

    Article  PubMed  CAS  Google Scholar 

  16. Qureshi AI, Safdar K, Weil J, et al. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke. 1995;26:1764–7.

    Article  PubMed  CAS  Google Scholar 

  17. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage [see comment]. Stroke. 2001;32:891–7.

    Article  PubMed  Google Scholar 

  18. Godoy DA, Pinero G, Di Napoli M. Predicting mortality in spontaneous intracerebral hemorrhage: can modification to original score improve the prediction? Stroke. 2006;37:1038–44.

    Article  PubMed  Google Scholar 

  19. Nilsson OG, Lindgren A, Brandt L, Saveland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg. 2002;97:531–6.

    Article  PubMed  Google Scholar 

  20. Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med. 2000;28:1556–64.

    Article  PubMed  CAS  Google Scholar 

  21. European Stroke Initiative Writing C, Writing Committee for the EEC, Katse M, et al. Recommendations for the management of intracranial haemorrhage—part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294–316.

    Google Scholar 

  22. St Louis EK, Wijdicks EF, Li H. Predicting neurologic deterioration in patients with cerebellar hematomas. Neurology. 1998;51:1364–9.

    PubMed  CAS  Google Scholar 

  23. Sumer MM, Acikgoz B, Akpinar G. External ventricular drainage for acute obstructive hydrocephalus developing following spontaneous intracerebral haemorrhages. Neurol Sci. 2002;23:29–33.

    Article  PubMed  Google Scholar 

  24. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage [see comment]. Crit Care Med. 1999;27:617–21.

    Article  PubMed  CAS  Google Scholar 

  25. Bhattathiri PS, Gregson B, Prasad KSM, Mendelow AD, Investigators S. Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. Acta Neurochir Suppl. 2006;96:65–8.

    Article  PubMed  CAS  Google Scholar 

  26. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767–73. discussion 773–764.

    Article  PubMed  Google Scholar 

  27. Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology. 1994;44:133–9.

    PubMed  CAS  Google Scholar 

  28. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41.

    Google Scholar 

  29. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.

    Article  PubMed  CAS  Google Scholar 

  30. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program 2004; http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed April 2011.

  31. Qureshi AI, Hutson AD, Harbaugh RE, et al. Methods and design considerations for randomized clinical trials evaluating surgical or endovascular treatments for cerebrovascular diseases. Neurosurgery. 2004;54:248–64. discussion 264–7.

    Article  PubMed  Google Scholar 

  32. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321:504.

    Article  PubMed  CAS  Google Scholar 

  33. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what [see comment]. Lancet. 2002;359:696–700.

    Article  PubMed  Google Scholar 

  34. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7.

    Article  PubMed  Google Scholar 

  35. Wilson JT, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33:2243–6.

    Article  PubMed  Google Scholar 

  36. Choi SC, Clifton GL, Marmarou A, Miller ER. Misclassification and treatment effect on primary outcome measures in clinical trials of severe neurotrauma. J Neurotrauma. 2002;19:17–22.

    Article  PubMed  Google Scholar 

  37. Mayer SA. Recombinant activated factor VII for acute intracerebral hemorrhage. Stroke. 2007;38:763–7.

    Article  PubMed  CAS  Google Scholar 

  38. Group TE. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:99–208.

    Google Scholar 

  39. Segal ME, Schall RR. Determining functional/health status and its relation to disability in stroke survivors. Stroke. 1994;25:2391–7.

    Article  PubMed  CAS  Google Scholar 

  40. Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P. Is the EuroQol a valid measure of health-related quality of life after stroke? Stroke. 1997;28:1876–82.

    Article  PubMed  CAS  Google Scholar 

  41. Dorman P, Slattery J, Farrell B, Dennis M, Sandercock P. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke. 1998;29:63–8.

    Article  PubMed  CAS  Google Scholar 

  42. Pickard AS, Johnson JA, Feeny DH, Shuaib A, Carriere KC, Nasser AM. Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. Stroke. 2004;35:607–12.

    Article  PubMed  Google Scholar 

  43. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke. 2007;38:2262–9.

    Article  PubMed  CAS  Google Scholar 

  44. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387–97.

    PubMed  Google Scholar 

  45. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.

    Article  PubMed  CAS  Google Scholar 

  46. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503–57.

    Article  PubMed  Google Scholar 

  47. Qureshi AI, Suri MFK, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke. 2007;38:2180–4.

    Article  PubMed  Google Scholar 

  48. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.

    Article  PubMed  CAS  Google Scholar 

  49. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–85.

    Article  PubMed  CAS  Google Scholar 

  50. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391–9.

    Article  PubMed  Google Scholar 

  51. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63:484–9.

    Article  PubMed  Google Scholar 

  52. Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009;37:S69–74.

    Article  PubMed  Google Scholar 

  53. Adams HP Jr. Trials of trials in acute ischemic stroke. The Humana lecture. Stroke. 1993;24:1410–5.

    Article  PubMed  Google Scholar 

  54. Bolland K, Sooriyarachchi MR, Whitehead J. Sample size review in a head injury trial with ordered categorical responses. Stat Med. 1998;17:2835–47.

    Article  PubMed  CAS  Google Scholar 

  55. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603–12.

    Article  PubMed  Google Scholar 

  56. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055–62.

    Article  PubMed  Google Scholar 

  57. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009;72:1310–5.

    Google Scholar 

  58. Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics. 1990;46:1171–8.

    Article  PubMed  CAS  Google Scholar 

  59. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215–22.

    Article  PubMed  Google Scholar 

  60. Lai SM, Duncan PW. Stroke recovery profile and the Modified Rankin assessment. Neuroepidemiology. 2001;20:26–30.

    Article  PubMed  CAS  Google Scholar 

  61. Feinstein AR, Landis JR. The role of prognostic stratification in preventing the bias permitted by random allocation of treatment. J Chronic Dis. 1976;29:277–84.

    Article  PubMed  CAS  Google Scholar 

  62. Lipchik GL, Nicholson RA, Penzien DB. Allocation of patients to conditions in headache clinical trials: randomization, stratification, and treatment matching [see comment]. Headache. 2005;45:419–28.

    Article  PubMed  Google Scholar 

  63. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials [see comment]. J Clin Epidemiol. 1999;52:19–26.

    Article  PubMed  CAS  Google Scholar 

  64. Beach ML, Meier P. Choosing covariates in the analysis of clinical trials. Control Clin Trials. 1989;10:161S–75S.

    Article  PubMed  CAS  Google Scholar 

  65. McHugh R, Matts J. Post-stratification in the randomized clinical trial. Biometrics. 1983;39:217–25.

    Article  PubMed  CAS  Google Scholar 

  66. Rectenwald JE, Upchurch GR Jr. Impact of outcomes research on the management of vascular surgery patients. J Vasc Surg. 2007;45(Suppl A):A131–40.

    Article  PubMed  Google Scholar 

  67. Lipscomb J, Donaldson MS, Hiatt RA. Cancer outcomes research and the arenas of application. J Natl Cancer Inst. 2004;Monographs:1–7.

    Google Scholar 

  68. Anonymous. Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke. 2005;36:e23–41.

    Article  Google Scholar 

  69. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation. 2006;113:456–62.

    Article  PubMed  Google Scholar 

  70. Taylor SM, Robison JG, Langan EM 3rd, Crane MM. The pitfalls of establishing a statewide vascular registry: the South Carolina experience. Am Surg. 1999;65:513–8. discussion 518-519.

    PubMed  CAS  Google Scholar 

  71. Isenberg SF. Community-based outcomes research: the project solo experience. Laryngoscope. 2000;110:21–3.

    Article  PubMed  CAS  Google Scholar 

  72. Qureshi AI, Suri MFK, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999–2001. Neurosurgery. 2005;57:647–54. discussion 647-654.

    Article  PubMed  Google Scholar 

  73. Qureshi AI, Kirmani JF, Sayed MA, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology. 2005;64:2115–20.

    Article  PubMed  CAS  Google Scholar 

  74. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM, Cleveland Clinic Health System Stroke Quality Improvement T. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34:799–800.

    Article  PubMed  CAS  Google Scholar 

  75. Anonymous. Comparison of patients with intracerebral hemorrhage treated within and outside clinical trials: A report of the antihypertensive treatment of acute cerebral hemorrhage investigators. In: American Academy of Neurology 59th Annual Meeting 2007. Boston. 2007.

  76. Qureshi AI. Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocrit Care. 2007;6:56–66.

    Article  PubMed  CAS  Google Scholar 

  77. Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–20.

    Article  PubMed  CAS  Google Scholar 

  78. Haley EC Jr, Thompson JL, Levin B, et al. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke. 2005;36:1006–10.

    Article  PubMed  CAS  Google Scholar 

  79. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism [see comment]. Stroke. 1998;29:4–11.

    Article  PubMed  CAS  Google Scholar 

  80. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism [see comment]. JAMA. 1999;282:2003–11.

    Article  PubMed  CAS  Google Scholar 

  81. Investigators IMSS. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study [see comment]. Stroke. 2004;35:904–11.

    Article  Google Scholar 

  82. Investigators IIT. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38:2127–35.

    Article  Google Scholar 

  83. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke. 2008;39:87–99.

    Article  PubMed  CAS  Google Scholar 

  84. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JN, Hussein HM, Suri MF, Tariq N, Antihypertensive Treatment of Acute Cerebral Hemorrhage Study Investigators. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010;67:570–6.

    Google Scholar 

Download references

Acknowledgement

The study is supported by National Institutes of Health grant 1U01NS062091-01A2. The study medication is provided by EKR Therapeutics, Inc., Bedminster, NJ.

Author information

Authors and Affiliations

  1. Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN, USA

    A. I. Qureshi

  2. Medical University of South Carolina, Charleston, SC, USA

    Y. Y. Palesch

  3. Department of Neurology, University of Minnesota, MMC 295, 420 Delaware Street SE, Minneapolis, MN, 55455, USA

    A. I. Qureshi

Authors
  1. A. I. Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Y. Palesch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. I. Qureshi.

Additional information

This study was conducted for the ATACH II Investigators.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qureshi, A.I., Palesch, Y.Y. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale. Neurocrit Care 15, 559–576 (2011). https://doi.org/10.1007/s12028-011-9538-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-011-9538-3

Keywords

Search

Navigation